160 related articles for article (PubMed ID: 29914143)
1. Preparation of Enzyme-Activated Thapsigargin Prodrugs by Solid-Phase Synthesis.
Zimmermann T; Christensen SB; Franzyk H
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914143
[TBL] [Abstract][Full Text] [Related]
2. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR
Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
4. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
5. Targeting thapsigargin towards tumors.
Doan NT; Paulsen ES; Sehgal P; Møller JV; Nissen P; Denmeade SR; Isaacs JT; Dionne CA; Christensen SB
Steroids; 2015 May; 97():2-7. PubMed ID: 25065587
[TBL] [Abstract][Full Text] [Related]
6. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
7. PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates.
Xu B; Zhou F; Yan MM; Cai DS; Guo WB; Yang YQ; Jia XH; Zhang WX; Li T; Ma T; Wang PL; Lei HM
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347770
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
Kularatne SA; Venkatesh C; Santhapuram HK; Wang K; Vaitilingam B; Henne WA; Low PS
J Med Chem; 2010 Nov; 53(21):7767-77. PubMed ID: 20936874
[TBL] [Abstract][Full Text] [Related]
9. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
10. Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Quynh Doan NT; Christensen SB
Curr Pharm Des; 2015; 21(38):5501-17. PubMed ID: 26429715
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
12. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.
Denmeade SR; Mhaka AM; Rosen DM; Brennen WN; Dalrymple S; Dach I; Olesen C; Gurel B; Demarzo AM; Wilding G; Carducci MA; Dionne CA; Møller JV; Nissen P; Christensen SB; Isaacs JT
Sci Transl Med; 2012 Jun; 4(140):140ra86. PubMed ID: 22745436
[TBL] [Abstract][Full Text] [Related]
13. Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics.
Isaacs JT; Brennen WN; Christensen SB; Denmeade SR
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946547
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
[TBL] [Abstract][Full Text] [Related]
15. Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer.
Martin SE; Ganguly T; Munske GR; Fulton MD; Hopkins MR; Berkman CE; Black ME
Bioconjug Chem; 2014 Oct; 25(10):1752-60. PubMed ID: 25157916
[TBL] [Abstract][Full Text] [Related]
16. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.
Christensen SB; Skytte DM; Denmeade SR; Dionne C; Møller JV; Nissen P; Isaacs JT
Anticancer Agents Med Chem; 2009 Mar; 9(3):276-94. PubMed ID: 19275521
[TBL] [Abstract][Full Text] [Related]
17. Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
Tokay E; Güngör T; Hacıoğlu N; Önder FC; Gülhan ÜG; Tok TT; Çelik A; Ay M; Köçkar F
Eur J Med Chem; 2020 Feb; 187():111937. PubMed ID: 31841727
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.
Jakobsen CM; Denmeade SR; Isaacs JT; Gady A; Olsen CE; Christensen SB
J Med Chem; 2001 Dec; 44(26):4696-703. PubMed ID: 11741487
[TBL] [Abstract][Full Text] [Related]
19. 2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
Akinboye ES; Rogers OC; Isaacs JT
Prostate; 2018 Jun; 78(9):655-663. PubMed ID: 29572902
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.
Wu X; Hu L
Bioorg Med Chem; 2016 Jun; 24(12):2697-706. PubMed ID: 27156193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
